Related Experiment Videos

Role of the cardiologist: clinical aspects of managing erectile dysfunction

Adolph M Hutter1

  • 1Department of Cardiology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. ahutter@partners.org

Clinical Cardiology
|April 30, 2004
PubMed

Insights

Erectile dysfunction (ED) often signals cardiovascular disease (CVD). Phosphodiesterase type 5 (PDE5) inhibitors are safe for most ED patients with CVD, but nitrate use requires caution.

Area of Science:

  • Cardiology
  • Urology
  • Pharmacology

Background:

  • Erectile dysfunction (ED) is a significant indicator of underlying cardiovascular disease (CVD).
  • Cardiologists play a crucial role in managing men with ED, who may not disclose symptoms due to embarrassment.
  • Identifying contributing factors like diabetes, depression, and cardiovascular risks is essential during clinical evaluation.

Purpose of the Study:

  • To highlight the link between ED and CVD.
  • To inform healthcare providers about the safe and effective use of phosphodiesterase type 5 (PDE5) inhibitors in patients with CVD.
  • To emphasize critical safety precautions regarding nitrate co-administration.

Main Methods:

  • Review of clinical guidelines and pharmacological data concerning ED and CVD.
  • Analysis of the safety and efficacy profile of PDE5 inhibitors in cardiovascular patients.
  • Examination of drug interaction data, particularly with nitrates.

Main Results:

  • PDE5 inhibitors are generally safe and effective for treating ED in patients with CVD, including those on antihypertensive medications.
  • These inhibitors do not adversely affect exercise capacity or induce ischemia in patients with CVD.
  • A critical contraindication exists for the concurrent use of PDE5 inhibitors and nitrates due to severe hypotension risk.

Conclusions:

  • ED warrants a thorough cardiovascular assessment.
  • PDE5 inhibitors represent a valuable therapeutic option for ED in the context of CVD.
  • Strict avoidance of nitrates in patients using PDE5 inhibitors is paramount for patient safety, with specific time intervals required after PDE5 inhibitor use before nitrate administration.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...